TC
TEVA icon

TwinBeech Capital’s Teva Pharmaceuticals TEVA Stock Holding History

TwinBeech Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-360,843
Closed -$2.72M – 891
2023
Q2 		$2.72M Buy
+360,843
New +$2.93M 0.05% 347

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

TwinBeech Capital's TEVA Position: Q3 2023 in Review

TwinBeech Capital sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 360,843 shares — an estimated $2.72M sold.

TwinBeech Capital first reported a position in TEVA in Q2 2023 and held it in 1 quarter. The position peaked at $2.72M in Q2 2023. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

  • TwinBeech Capital reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • TwinBeech Capital sold 360,843 Teva Pharmaceuticals shares in Q3 2023, an estimated $2.72M.
  • TwinBeech Capital first reported a position in Teva Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • TwinBeech Capital's Teva Pharmaceuticals position peaked at $2.72M in Q2 2023.
  • 435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on TwinBeech Capital's 13F filing for Q3 2023, filed 14 Nov 2023.